BASILEA

Serial Number 88633518
606

Registration Progress

Application Filed
Sep 27, 2019
Under Examination
Apr 7, 2020
Approved for Publication
Feb 11, 2020
Published for Opposition
Feb 11, 2020
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: BASILEA
Previous Owner: Basilea Pharmaceutica AG
Classes: 001, 005, 042

Trademark Image

BASILEA

Basic Information

Serial Number
88633518
Filing Date
September 27, 2019
Published for Opposition
February 11, 2020
Abandonment Date
May 8, 2023
Drawing Code
3

Status Summary

Current Status
Inactive
Status Code
606
Status Date
May 8, 2023
Classes
001 005 042

Rights Holder

Basilea Pharmaceutica AG

03
Address
Grenzacherstrasse 487
Basel 4058
CH

Ownership History

Basilea Pharmaceutica AG

Original Applicant
03
Basel CH

Basilea Pharmaceutica AG

Owner at Publication
03
Basel CH

Legal Representation

Attorney
Evan A. Raynes

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

32 events
Date Code Type Description Documents
May 8, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
May 8, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 6, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 5, 2022 EX5G S SOU EXTENSION 5 GRANTED Loading...
Sep 21, 2022 EXT5 S SOU EXTENSION 5 FILED Loading...
Oct 2, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 21, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 11, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 9, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Mar 9, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Mar 9, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 25, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 23, 2021 EX3G S SOU EXTENSION 3 GRANTED Loading...
Sep 23, 2021 EXT3 S SOU EXTENSION 3 FILED Loading...
Sep 23, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 18, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 16, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Mar 16, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 16, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 23, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 21, 2020 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 21, 2020 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 21, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 7, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 11, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 11, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 22, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 31, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 31, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 3, 2019 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Oct 2, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 1, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 001
Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
Class 005
Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
Class 042
Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations

Additional Information

Design Mark
The mark consists of the word "BASILEA" surrounded by an oval.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
001 005 042